188 related articles for article (PubMed ID: 10960471)
1. Characterization of the binding site on the formyl peptide receptor using three receptor mutants and analogs of Met-Leu-Phe and Met-Met-Trp-Leu-Leu.
Mills JS; Miettinen HM; Cummings D; Jesaitis AJ
J Biol Chem; 2000 Dec; 275(50):39012-7. PubMed ID: 10960471
[TBL] [Abstract][Full Text] [Related]
2. A single amino acid substitution (N297A) in the conserved NPXXY sequence of the human N-formyl peptide receptor results in inhibition of desensitization and endocytosis, and a dose-dependent shift in p42/44 mitogen-activated protein kinase activation and chemotaxis.
Gripentrog JM; Jesaitis AJ; Miettinen HM
Biochem J; 2000 Dec; 352 Pt 2(Pt 2):399-407. PubMed ID: 11085933
[TBL] [Abstract][Full Text] [Related]
3. Identification of a ligand binding site in the human neutrophil formyl peptide receptor using a site-specific fluorescent photoaffinity label and mass spectrometry.
Mills JS; Miettinen HM; Barnidge D; Vlases MJ; Wimer-Mackin S; Dratz EA; Sunner J; Jesaitis AJ
J Biol Chem; 1998 Apr; 273(17):10428-35. PubMed ID: 9553101
[TBL] [Abstract][Full Text] [Related]
4. The ligand binding site of the formyl peptide receptor maps in the transmembrane region.
Miettinen HM; Mills JS; Gripentrog JM; Dratz EA; Granger BL; Jesaitis AJ
J Immunol; 1997 Oct; 159(8):4045-54. PubMed ID: 9378994
[TBL] [Abstract][Full Text] [Related]
5. Mutations of F110 and C126 of the formyl peptide receptor interfere with G-protein coupling and chemotaxis.
Jones BE; Miettinen HM; Jesaitis AJ; Mills JS
J Periodontol; 2003 Apr; 74(4):475-84. PubMed ID: 12747452
[TBL] [Abstract][Full Text] [Related]
6. Identification of putative sites of interaction between the human formyl peptide receptor and G protein.
Miettinen HM; Gripentrog JM; Mason MM; Jesaitis AJ
J Biol Chem; 1999 Sep; 274(39):27934-42. PubMed ID: 10488141
[TBL] [Abstract][Full Text] [Related]
7. Critical role of N-terminal N-glycosylation for proper folding of the human formyl peptide receptor.
Wenzel-Seifert K; Seifert R
Biochem Biophys Res Commun; 2003 Feb; 301(3):693-8. PubMed ID: 12565836
[TBL] [Abstract][Full Text] [Related]
8. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor.
He R; Tan L; Browning DD; Wang JM; Ye RD
J Immunol; 2000 Oct; 165(8):4598-605. PubMed ID: 11035102
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of the N-formyl peptide receptor is required for receptor internalization but not chemotaxis.
Hsu MH; Chiang SC; Ye RD; Prossnitz ER
J Biol Chem; 1997 Nov; 272(47):29426-9. PubMed ID: 9367998
[TBL] [Abstract][Full Text] [Related]
10. T21/DP107, A synthetic leucine zipper-like domain of the HIV-1 envelope gp41, attracts and activates human phagocytes by using G-protein-coupled formyl peptide receptors.
Su SB; Gao Jl; Gong Wh; Dunlop NM; Murphy PM; Oppenheim JJ; Wang JM
J Immunol; 1999 May; 162(10):5924-30. PubMed ID: 10229829
[TBL] [Abstract][Full Text] [Related]
11. The non-steroidal anti-inflammatory drug piroxicam blocks ligand binding to the formyl peptide receptor but not the formyl peptide receptor like 1.
Stenfeldt AL; Karlsson J; Wennerås C; Bylund J; Fu H; Dahlgren C
Biochem Pharmacol; 2007 Oct; 74(7):1050-6. PubMed ID: 17692291
[TBL] [Abstract][Full Text] [Related]
12. Arrestin binding to the G protein-coupled N-formyl peptide receptor is regulated by the conserved "DRY" sequence.
Bennett TA; Maestas DC; Prossnitz ER
J Biol Chem; 2000 Aug; 275(32):24590-4. PubMed ID: 10823817
[TBL] [Abstract][Full Text] [Related]
13. T20/DP178, an ectodomain peptide of human immunodeficiency virus type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor.
Su SB; Gong WH; Gao JL; Shen WP; Grimm MC; Deng X; Murphy PM; Oppenheim JJ; Wang JM
Blood; 1999 Jun; 93(11):3885-92. PubMed ID: 10339497
[TBL] [Abstract][Full Text] [Related]
14. Human formyl peptide receptor ligand binding domain(s). Studies using an improved mutagenesis/expression vector reveal a novel mechanism for the regulation of receptor occupancy.
Perez HD; Vilander L; Andrews WH; Holmes R
J Biol Chem; 1994 Sep; 269(36):22485-7. PubMed ID: 8077194
[TBL] [Abstract][Full Text] [Related]
15. Binding of low affinity N-formyl peptide receptors to G protein. Characterization of a novel inactive receptor intermediate.
Prossnitz ER; Schreiber RE; Bokoch GM; Ye RD
J Biol Chem; 1995 May; 270(18):10686-94. PubMed ID: 7738006
[TBL] [Abstract][Full Text] [Related]
16. High constitutive activity of the human formyl peptide receptor.
Wenzel-Seifert K; Hurt CM; Seifert R
J Biol Chem; 1998 Sep; 273(37):24181-9. PubMed ID: 9727041
[TBL] [Abstract][Full Text] [Related]
17. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
[TBL] [Abstract][Full Text] [Related]
18. Multiple domains of the N-formyl peptide receptor are required for high-affinity ligand binding. Construction and analysis of chimeric N-formyl peptide receptors.
Quehenberger O; Prossnitz ER; Cavanagh SL; Cochrane CG; Ye RD
J Biol Chem; 1993 Aug; 268(24):18167-75. PubMed ID: 8349692
[TBL] [Abstract][Full Text] [Related]
19. The N-formylpeptide receptor (FPR) and a second G(i)-coupled receptor mediate fMet-Leu-Phe-stimulated activation of NADPH oxidase in murine neutrophils.
Lavigne MC; Murphy PM; Leto TL; Gao JL
Cell Immunol; 2002; 218(1-2):7-12. PubMed ID: 12470609
[TBL] [Abstract][Full Text] [Related]
20. The NH2-terminal region of C5aR but not that of FPR is critical for both protein transport and ligand binding.
Mery L; Boulay F
J Biol Chem; 1994 Feb; 269(5):3457-63. PubMed ID: 8106386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
